midodrine has been researched along with Recrudescence in 17 studies
Midodrine: An ethanolamine derivative that is an adrenergic alpha-1 agonist. It is used as a vasoconstrictor agent in the treatment of HYPOTENSION.
midodrine : An aromatic ether that is 1,4-dimethoxybenzene which is substituted at position 2 by a 2-(glycylamino)-1-hydroxyethyl group. A direct-acting sympathomimetic with selective alpha-adrenergic agonist activity, it is used (generally as its hydrochloride salt) as a peripheral vasoconstrictor in the treatment of certain hypotensive states. The main active moiety is its major metabolite, deglymidodrine.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Forty cirrhotic patients with refractory or recurrent ascites were prospectively studied after long term administration of midodrine plus standard medical therapy (n=20) or standard medical therapy alone (n=20) in a randomized controlled trial at a tertiary centre." | 9.16 | Midodrine in patients with cirrhosis and refractory or recurrent ascites: a randomized pilot study. ( Bhalla, A; Dhungana, SP; Gupta, PK; Nain, CK; Sharma, N; Singh, B; Singh, V; Vijayverghia, R, 2012) |
| " The pharmacokinetic characteristics of the prodrug midodrine and the active metabolite de-glymidodrine in this patient with end-stage renal disease approximate those reported for patients with normal renal function." | 5.29 | Midodrine efficacy and pharmacokinetics in a patient with recurrent intradialytic hypotension. ( Balfe, JW; Blowey, DL; Gajaria, MM; Gupta, I; Koren, G, 1996) |
| "Forty cirrhotic patients with refractory or recurrent ascites were prospectively studied after long term administration of midodrine plus standard medical therapy (n=20) or standard medical therapy alone (n=20) in a randomized controlled trial at a tertiary centre." | 5.16 | Midodrine in patients with cirrhosis and refractory or recurrent ascites: a randomized pilot study. ( Bhalla, A; Dhungana, SP; Gupta, PK; Nain, CK; Sharma, N; Singh, B; Singh, V; Vijayverghia, R, 2012) |
| " After one week the dosage will be up-titrated to midodrine 30 mg/day and fludrocortisone 0." | 3.01 | Comparison of Outcomes with Midodrine and Fludrocortisone for Objective Recurrence in Treating Syncope (COMFORTS trial): Rationale and design for a multi-center randomized controlled trial. ( Akbarzadeh, MA; Alaeddini, F; Aminorroaya, A; Apakuppakul, S; Ariannejad, H; Bozorgi, A; Emkanjoo, Z; Jalali, A; Joharimoghadam, A; Kiarsi, M; Mohammadi, R; Mohsenizade, A; Mollazadeh, R; Ngarmukos, T; Oraii, A; Oraii, S; Rahimi, B; Sadeghian, S; Shahabi, J; Tajdini, M; Tavolinejad, H, 2021) |
| "Initial treatment of vasovagal syncope (VVS) consists of advising adequate fluid and salt intake, regular exercise, and physical counterpressure manoeuvres." | 2.76 | Effectiveness of midodrine treatment in patients with recurrent vasovagal syncope not responding to non-pharmacological treatment (STAND-trial). ( Go-Schön, IK; Reitsma, JB; Romme, JJ; van Dijk, N; Wieling, W, 2011) |
| "Midodrine was given at a starting dose of 5 mg three times a day and increased up to a dose of 15 mg three times a day when required." | 2.70 | Usefulness of midodrine in patients with severely symptomatic neurocardiogenic syncope: a randomized control study. ( Akhtar, M; Bash, D; Beheiry, S; Jaeger, F; Leonelli, FM; Natale, A; Pavia, S; Perez-Lugones, A; Saliba, W; Schweikert, R; Shewchik, J; Sra, J; Tchou, PJ; Tomassoni, GF, 2001) |
| "Therapy of vasovagal syncope is still a subject of debate." | 2.69 | Midodrine hydrochloride in the treatment of vasovagal syncope. ( Mitro, P; Rybár, AR; Trejbal, D, 1999) |
| "Vasovagal syncope is the most common cause of syncope in childhood and its treatment is not at a satisfactory level yet." | 1.62 | Midodrine treatment in children with recurrent vasovagal syncope. ( Atik, F; Bagrul, D; Ece, I; Kavurt, AV; Yılmaz, A, 2021) |
| "Pharmacological therapy of neurocardiogenic syncope is often limited by the relatively low response rate to such treatment." | 1.30 | Prospective evaluation of a two-step therapeutic strategy in neurocardiogenic syncope: midodrine as second line treatment in patients refractory to beta-blockers. ( Credner, S; Hohnloser, SH; Klingenheben, T, 1999) |
| " The pharmacokinetic characteristics of the prodrug midodrine and the active metabolite de-glymidodrine in this patient with end-stage renal disease approximate those reported for patients with normal renal function." | 1.29 | Midodrine efficacy and pharmacokinetics in a patient with recurrent intradialytic hypotension. ( Balfe, JW; Blowey, DL; Gajaria, MM; Gupta, I; Koren, G, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (29.41) | 18.2507 |
| 2000's | 6 (35.29) | 29.6817 |
| 2010's | 3 (17.65) | 24.3611 |
| 2020's | 3 (17.65) | 2.80 |
| Authors | Studies |
|---|---|
| Shaughnessy, AF | 1 |
| Bagrul, D | 1 |
| Ece, I | 1 |
| Yılmaz, A | 1 |
| Atik, F | 1 |
| Kavurt, AV | 1 |
| Aminorroaya, A | 1 |
| Tavolinejad, H | 1 |
| Sadeghian, S | 1 |
| Jalali, A | 1 |
| Alaeddini, F | 1 |
| Emkanjoo, Z | 1 |
| Mollazadeh, R | 1 |
| Bozorgi, A | 1 |
| Oraii, S | 1 |
| Kiarsi, M | 1 |
| Shahabi, J | 1 |
| Akbarzadeh, MA | 1 |
| Rahimi, B | 1 |
| Joharimoghadam, A | 1 |
| Mohsenizade, A | 1 |
| Mohammadi, R | 1 |
| Oraii, A | 1 |
| Ariannejad, H | 1 |
| Apakuppakul, S | 1 |
| Ngarmukos, T | 1 |
| Tajdini, M | 1 |
| Sivakumar, P | 1 |
| Ahmed, L | 1 |
| Singh, V | 1 |
| Dhungana, SP | 1 |
| Singh, B | 1 |
| Vijayverghia, R | 1 |
| Nain, CK | 1 |
| Sharma, N | 1 |
| Bhalla, A | 1 |
| Gupta, PK | 1 |
| Romme, JJ | 1 |
| van Dijk, N | 1 |
| Go-Schön, IK | 1 |
| Reitsma, JB | 1 |
| Wieling, W | 1 |
| Credner, SC | 1 |
| Lehmann, R | 1 |
| Grubb, BP | 2 |
| Hohnloser, SH | 2 |
| Klingenheben, T | 2 |
| Platts, SH | 1 |
| Ziegler, MG | 1 |
| Waters, WW | 1 |
| Mitchell, BM | 1 |
| Meck, JV | 1 |
| Gierelak, G | 1 |
| Makowski, K | 1 |
| Guzik, P | 1 |
| Kramarz, E | 1 |
| Kowal, J | 1 |
| Cholewa, M | 1 |
| Amaki, M | 1 |
| Kamide, K | 1 |
| Takiuchi, S | 1 |
| Niizuma, S | 1 |
| Horio, T | 1 |
| Kawano, Y | 1 |
| Ward, C | 1 |
| Kenny, RA | 1 |
| Blowey, DL | 1 |
| Balfe, JW | 1 |
| Gupta, I | 1 |
| Gajaria, MM | 1 |
| Koren, G | 1 |
| Credner, S | 1 |
| Karas, B | 1 |
| Kosinski, D | 1 |
| Boehm, K | 1 |
| Mitro, P | 1 |
| Trejbal, D | 1 |
| Rybár, AR | 1 |
| Perez-Lugones, A | 1 |
| Schweikert, R | 1 |
| Pavia, S | 1 |
| Sra, J | 1 |
| Akhtar, M | 1 |
| Jaeger, F | 1 |
| Tomassoni, GF | 1 |
| Saliba, W | 1 |
| Leonelli, FM | 1 |
| Bash, D | 1 |
| Beheiry, S | 1 |
| Shewchik, J | 1 |
| Tchou, PJ | 1 |
| Natale, A | 1 |
| Wiley, TM | 1 |
| Luu, VD | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Compression Stockings for Treating Vasovagal Syncope (COMFORTS II) Trial; a Double Blind, Multi-center Randomized Controlled Trial[NCT05086679] | 268 participants (Anticipated) | Interventional | 2022-03-14 | Recruiting | |||
| Comparison of Outcomes With Midodrine and Fludrocortisone for Objective Recurrence in Treating Syncope (COMFORTS Trial)[NCT04595942] | Phase 3 | 1,375 participants (Anticipated) | Interventional | 2020-11-19 | Recruiting | ||
| Safety and Efficacy of Midodrine Hydrochloride in the Management of Refractory Ascites Due to Cirrhosis in Children: a Pilot Study[NCT04043858] | 20 participants (Anticipated) | Interventional | 2020-06-05 | Recruiting | |||
| Effects of Adding Hypertonic Saline Solutions and/or Etilefrine to Standard Diuretics Therapy in Egyptian Cirrhotic Patients With Ascites[NCT04785755] | Phase 2 | 90 participants (Actual) | Interventional | 2017-11-30 | Completed | ||
| CardioneuROablation for Reflex Syncope: Effects on autonoMic cArdiac Regulation and Efficacy Assessment - the Roman Syncope Study.[NCT03903744] | 48 participants (Actual) | Interventional | 2018-11-01 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
7 trials available for midodrine and Recrudescence
| Article | Year |
|---|---|
Comparison of Outcomes with Midodrine and Fludrocortisone for Objective Recurrence in Treating Syncope (COMFORTS trial): Rationale and design for a multi-center randomized controlled trial.
Topics: Adrenergic alpha-1 Receptor Agonists; Anti-Inflammatory Agents; Drug Therapy, Combination; Fludrocor | 2021 |
Comparison of Outcomes with Midodrine and Fludrocortisone for Objective Recurrence in Treating Syncope (COMFORTS trial): Rationale and design for a multi-center randomized controlled trial.
Topics: Adrenergic alpha-1 Receptor Agonists; Anti-Inflammatory Agents; Drug Therapy, Combination; Fludrocor | 2021 |
Comparison of Outcomes with Midodrine and Fludrocortisone for Objective Recurrence in Treating Syncope (COMFORTS trial): Rationale and design for a multi-center randomized controlled trial.
Topics: Adrenergic alpha-1 Receptor Agonists; Anti-Inflammatory Agents; Drug Therapy, Combination; Fludrocor | 2021 |
Comparison of Outcomes with Midodrine and Fludrocortisone for Objective Recurrence in Treating Syncope (COMFORTS trial): Rationale and design for a multi-center randomized controlled trial.
Topics: Adrenergic alpha-1 Receptor Agonists; Anti-Inflammatory Agents; Drug Therapy, Combination; Fludrocor | 2021 |
Midodrine in patients with cirrhosis and refractory or recurrent ascites: a randomized pilot study.
Topics: Adrenergic alpha-1 Receptor Agonists; Adult; Ascites; Female; Hemodynamics; Humans; Kidney; Liver Ci | 2012 |
Midodrine in patients with cirrhosis and refractory or recurrent ascites: a randomized pilot study.
Topics: Adrenergic alpha-1 Receptor Agonists; Adult; Ascites; Female; Hemodynamics; Humans; Kidney; Liver Ci | 2012 |
Midodrine in patients with cirrhosis and refractory or recurrent ascites: a randomized pilot study.
Topics: Adrenergic alpha-1 Receptor Agonists; Adult; Ascites; Female; Hemodynamics; Humans; Kidney; Liver Ci | 2012 |
Midodrine in patients with cirrhosis and refractory or recurrent ascites: a randomized pilot study.
Topics: Adrenergic alpha-1 Receptor Agonists; Adult; Ascites; Female; Hemodynamics; Humans; Kidney; Liver Ci | 2012 |
Effectiveness of midodrine treatment in patients with recurrent vasovagal syncope not responding to non-pharmacological treatment (STAND-trial).
Topics: Adrenergic alpha-1 Receptor Agonists; Adult; Cross-Over Studies; Double-Blind Method; Exercise; Fema | 2011 |
Observations on midodrine in a case of vasodepressor neurogenic syncope.
Topics: Adrenergic alpha-Agonists; Adult; Blood Pressure; Cardiac Pacing, Artificial; Cross-Over Studies; El | 1995 |
Preliminary observations on the use of midodrine hydrochloride in the treatment of refractory neurocardiogenic syncope.
Topics: Administration, Oral; Adolescent; Adrenergic alpha-Agonists; Adult; Aged; Autonomic Nervous System D | 1999 |
Midodrine hydrochloride in the treatment of vasovagal syncope.
Topics: Adrenergic alpha-Agonists; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; F | 1999 |
Usefulness of midodrine in patients with severely symptomatic neurocardiogenic syncope: a randomized control study.
Topics: Adrenergic alpha-Agonists; Adult; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Human | 2001 |
10 other studies available for midodrine and Recrudescence
| Article | Year |
|---|---|
Midodrine Is Worth a Trial in People With Frequent Episodes of Vasovagal Syncope.
Topics: Humans; Midodrine; Recurrence; Syncope, Vasovagal | 2022 |
Midodrine treatment in children with recurrent vasovagal syncope.
Topics: Adolescent; Child; Humans; Midodrine; Recurrence; Retrospective Studies; Syncope, Vasovagal | 2021 |
Use of an Alpha-1 Adrenoreceptor Agonist in the Management of Recurrent Refractory Idiopathic Chylothorax.
Topics: Adrenergic alpha-1 Receptor Agonists; Aged; Chylothorax; Female; Follow-Up Studies; Humans; Midodrin | 2018 |
Recurrent syncope in a patient after myocardial infarction.
Topics: Aged; Humans; Male; Midodrine; Myocardial Infarction; Recurrence; Sympathomimetics; Syncope | 2003 |
Midodrine prescribed to improve recurrent post-spaceflight orthostatic hypotension.
Topics: Adrenergic alpha-Agonists; Cardiac Output; Female; Heart Rate; Humans; Hypotension, Orthostatic; Mid | 2004 |
Effects of therapy based on tilt testing results on the long-term outcome in patients with syncope.
Topics: Adolescent; Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adult; Aged; Female; Fludroco | 2005 |
A case of neurally mediated syncope induced by laughter successfully treated with combination of propranolol and midodrine.
Topics: Adrenergic alpha-Agonists; Adrenergic beta-Antagonists; Aged; Drug Therapy, Combination; Electrocard | 2007 |
Midodrine efficacy and pharmacokinetics in a patient with recurrent intradialytic hypotension.
Topics: Adolescent; Adrenergic alpha-Agonists; Half-Life; Humans; Hypotension; Kidney Failure, Chronic; Male | 1996 |
Prospective evaluation of a two-step therapeutic strategy in neurocardiogenic syncope: midodrine as second line treatment in patients refractory to beta-blockers.
Topics: Adrenergic alpha-Agonists; Adrenergic beta-Antagonists; Clinical Protocols; Female; Follow-Up Studie | 1999 |
Recurrent syncope in a 31-year-old army staff sergeant.
Topics: Adrenergic alpha-Agonists; Adrenergic beta-Antagonists; Adult; Atenolol; Case Management; Humans; Ma | 2002 |